Mental DailyMental Daily
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • My Bookmarks
Aa
Mental Daily
Aa
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • Opinion
Search
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • My Bookmarks
Follow US
  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store
© 2022 - Mental Daily. All Rights Reserved.
Clinical

The psychedelic ibogaine may be useful for psychiatric disorders, including addiction

Staff Writer
Staff Writer 3 years ago
Updated 2021/10/23 at 2:11 PM
Share
SHARE

The psychedelic drug known as ibogaine may be useful for treating several psychiatric disorders, including addiction, new research in the journal Nature concluded.

Derived from the plant Tabernanthe iboga, a team at UC Davis set out to experiment on the ibogaine drug but without administering its psychedelic compound, which may be undesirable as a therapeutic treatment.

The study led to the creation of a new synthetic, water-soluble molecule called tabernanthalog.

“Here we apply the principles of function-oriented synthesis to identify the key structural elements of the potential therapeutic pharmacophore of ibogaine, and we use this information to engineer tabernanthalog—a water-soluble, non-hallucinogenic, non-toxic analogue of ibogaine that can be prepared in a single step,” the study says.

Researchers utilized rodents to experiment with tabernanthalog and established its impact on structural neural plasticity, enabling its use for therapeutic means.

Tabernanthalog, overall, was shown to reduce addiction-like behavior among the rodents, as well as producing antidepressant-like effects deemed to be of significant therapeutic potential.

“In rodents, tabernanthalog was found to promote structural neural plasticity, reduce alcohol- and heroin-seeking behaviour, and produce antidepressant-like effects,” the co-authors wrote in their Nature article.

“This work demonstrates that, through careful chemical design, it is possible to modify a psychedelic compound to produce a safer, non-hallucinogenic variant that has therapeutic potential.”

Photo: stuart elmes

You Might Also Like

Study boasts MDMA-assisted therapy for PTSD patients

How the brain is organized is revealed by the largest genetic study of brain structure to date

Study investigates the ethical implications of combining the analysis of ancient DNA and data from private genetic databases

New study reveals positive results from postpartum depression treatment Zuranolone

New study explores magic mushrooms for anorexia nervosa psychopathology

TAGGED: ibogaine, mental health, psychodelics, drugs
Staff Writer December 9, 2020
Share this Article
Facebook Twitter Whatsapp Whatsapp Email Print
Previous Article Oxford’s COVID-19 vaccine is nearly half as effective as Pfizer’s vaccine
Next Article Consuming asthma medicines during pregnancy may raise the risk of premature births and small birth weight

Recommended

Clinical

Study boasts MDMA-assisted therapy for PTSD patients

1 Min Read
Clinical

How the brain is organized is revealed by the largest genetic study of brain structure to date

2 Min Read
Clinical

Study investigates the ethical implications of combining the analysis of ancient DNA and data from private genetic databases

3 Min Read
Clinical

New study reveals positive results from postpartum depression treatment Zuranolone

2 Min Read
//

We are a trusted online source for research news and resources on all aspects of the mind and human behavior.

Verticals

  • Clinical
  • Health
  • Social
  • I/O
  • Opinion

Social

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Links

  • About
  • Contact
  • The Editor
  • Terms & Conditions
  • Privacy Policy
Follow US

© 2022 Mental Daily. All Rights Reserved.

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?